Based on the big promise of GlaxoSmithKline's ($GSK) dolutegravir, the FDA has granted the potential HIV drug a priority review of 6 months rather than the standard 10 months. The agency gave an Aug. 17 action date for its review of the drug. London-based GSK controls a majority stake in the product, which is owned by its ViiV Healthcare joint venture with Pfizer ($PFE). Analysts believe that dolutegravir could be a multibillion-dollar seller which competes well with HIV drug powerhouse Gilead Sciences' ($GILD) meds. Article